Oxford, UK and Houston, TX – January 8, 2026 – Optellum, the leader in AI-enabled lung cancer prediction, today announced the closure of its Series B funding round. The round included new investment from Woori Venture Partners, the venture arm of Woori Financial Group, and Healthliant Ventures, the venture arm of the US health system Tanner Health, alongside continued support from existing investors Mercia Ventures, Intuitive Ventures, and Black Opal Ventures.

The investment will support Optellum’s next phase of growth as well as expansion of its portfolio of AI and foundation model-enabled products for precision lung care. Optellum’s FDA-cleared solution, with CPT coding as well as Medicare and commercial reimbursement, is already used in numerous health systems across the United States and internationally. Leading institutions such as Vanderbilt University Medical Center, Atrium Health Wake Forest Baptist, and University of Pennsylvania Health System use the platform to enable earlier, more accurate decision-making for patients with pulmonary nodules and lung cancer.

“Over the past several years, Optellum has demonstrated that meaningful clinical and commercial progress in AI-enabled lung care is possible when you combine world-class science with disciplined execution and strong customer partnerships,” said Johnathan Watkins, Chief Executive Officer at Optellum.

“We are excited to back Optellum’s ambition to redefine precision lung care through AI. We look forward to partnering closely with the Optellum team to accelerate its global impact.” noted Chihoon Hyun, Head of Global Investment Group, Woori Venture Partners.

“Optellum’s AI solution aligns perfectly with our mission to provide quality healthcare services and serve as a leader in the community to provide health education, support services and care for all of our citizens,” said Loy Howard, president and CEO of Tanner Health.

About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.

Optellum’s flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world’s first and only FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum’s solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians’ efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, and UKCA marked.

Optellum is headquartered in Oxford, UK, and has an office at the Texas Medical Center in Houston, Texas, US.

For more information, visit optellum.com or connect with us on LinkedIn.